CAR T cell generation and functional validation of newly identified CAR T cell targets.
Schäfer, D. et al. (2021) Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nature Communications 12: 1453. https://doi.org/10.1038/s41467-021-21774-4
Establishment of a novel humanized artificial receptor platform termed RevCARs for CAR T cell optimization. Pan T cell activation using T Cell TransAct.
Feldmann, A. et al. (2020) Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. Oncoimmunology 9: 1785608. https://doi: 10.1080/2162402X.2020.1785608
Investigation of iPSC-derived T cell functionality (cell proliferation and expression of activation marker) by responding to T Cell TransAct-mediated TCR activation.
Netsrithong, R. et al. (2020) Multilineage differentiation potential of hematoendothelial progenitors derived from human induced pluripotent stem cells. Stem Cell Research & Therapy 11: 481. https://doi.org/10.1186/s13287-020-01997-w
Engineering of an affinity-matured human antibody that mediates antibody dependent cellular cytotoxicity of mutant p53 expressing cells in vitro.
Low, L. et al. (2019) Targeting mutant p53-expressing tumours with a T cell receptor–like antibody specific for a wild-type antigen. Nat. Commun. 10: 5382. https://doi.org/10.1038/s41467-019-13305-z